Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775275 | 0.83 | EGFR (0.51) | MAPTMAP4K4EGFRTRPA1 | |
| SCHEMBL24067380 | 0.82 | MAPT (0.43) | KMT2ANPC1MAPTRAB9ACAMKK1 | |
| SCHEMBL25671081 | 0.80 | CAMKK1 (0.44) | KMT2AMAPTRAB9ASMN1; SMN2MAP4K4 | |
| SCHEMBL24067371 | 0.79 | MAPK7 (0.41) | NPC1RAB9ASMN1; SMN2MAPK7EGFR | |
| SCHEMBL22749328 | 0.78 | PDE4A (0.44) | KMT2ANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20813472 | 0.78 | KMT2A (0.42) | KMT2ANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25841942 | 0.77 | PDGFRB (0.33) | KMT2ANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20047527 | 0.76 | EGFR (0.36) | KMT2ANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25670590 | 0.75 | SRC (0.38) | EGFR | |
| SCHEMBL4548618 | 0.74 | KIF11 (0.36) | KMT2AMAPTPDGFRBEGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | KMT2A 3582/4885NPC1 923/4885MAPT 3612/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | KMT2A 4630/4885NPC1 657/4885MAPT 3849/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | KMT2A 3582/4885NPC1 923/4885MAPT 3612/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | KMT2A 3582/4885NPC1 923/4885MAPT 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.